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ABSTRACT
Introduction
The National Cancer Institute of Canada Clinical Trials Group CO. 17 trial
and the Open-Label Phase III trial showed that the addition of new anti-EGFR
monoclonal antibodies (cetuximab andpanitumumab) to best supportive care as
third-line treatments prolong the life of patients with advanced metastatic
colorectal cancer, but have also introduced a unique set of toxicities and
increased costs. In a resource constrained environment this prompts the need for
tools to identify the patients who are likely to benefit from these therapies in a
more efficient and cost-effective way.
We developed an economic model using analytic decision modeling to
assess the cost-effectiveness of two anti-EGFR monoclonal antibodies
(cetuximab and panitumumab) plus best supportive care versus best supportive
care alone as third-line treatment in advanced chemorefractory metastatic
colorectal cancer.
Methods
We constructed a Markov model based on the efficacy data obtained from
the National Cancer Institute of Canada Clinical Trials Group CO. 17 trial and the
Open-Label Phase III trial studies. Costs for physician visits, blood products,
emergency department visits, hospitalizations and toxicity management were
obtained published literature and expert opinion. Drug costs were obtained from
London Health Sciences Center (LHSC) drug formulary intranet. The primary
outcome of the model is the incremental cost-utility ratio of adding anti-EGFR
monoclonal antibodies (panitumumab and cetuximab) to best supportive care as
third-line therapies in treatment of advanced metastatic chemo-refractory
colorectal cancer, expressed as cost per quality-adjusted life year (QALY)
gained. A series of deterministic and probabilistic sensitivity analyses were also
performed to account for uncertainty in the model parameters.
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Results
Adding panitumumab to best supportive care (with KRAS test) resulted in
a mean gain of 0.087 QALYs with a mean incremental cost utility ratio of
$269,703 per QALY gained (95% Cl = $135,432 to $766,072 per QALY gained).
The addition of cetuximab to best supportive care (with KRAS test) resulted in a
mean gain of 0.068 QALYs with a mean incremental cost-utility ratio of $352,046
per QALY gained (95% Cl = $151,916 to $949,342 per QALY gained). In subset
of patients with wild-type KRAS, the addition of panitumumab to best supportive
care resulted in a mean gain of 0.16 QALYs with a mean incremental cost-utility
ratio of $236,469 per QALY gained (95% Cl = $125,259 to $557,750 per QALY
gained).
Conclusions
From a health economic perspective, both anti-EFGR therapies
(panitumumab and cetuximab) showed very high Incremental cost-utility ratios
and were not cost-effective at a willingness-to-pay threshold of $100,000 per
QALY. The cost-utility ratios were much more favorable in subset of patients with
wild-type KRAS. This suggests that personalizing advanced metastatic colorectal
cancer treatment based on KRAS mutation status could not only save health
care system substantial sums but also spare thousands of patients with
metastatic colorectal cancer from side effects of the anti-EGFR therapies that are
unlikely to benefit from the treatment.

Keywords
Epidermal growth factor receptor, Anti-EGFR monoclonal antibodies, KRAS
oncogene, Colorectal, Incremental cost-utility ratio, Quality-adjusted life year,
Probabilistic sensitivity analysis.
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Chapter 1: Introduction
Colorectal cancer is the third most common cancer and the second most
common cause of death due to cancer among Canadians [1], According to
Statistics Canada, in 2010 an estimated 22,500 Canadians will be diagnosed
with colorectal cancer and 9,100 will die from it [1],
The life expectancy of metastatic colorectal cancer patients who receive
best supportive care without chemotherapy is about five to six months [2-3], The
current use of standard chemotherapy such as 5-fluourouracil and leucovorin
along with adjuvant chemotherapy such as irinotecan, oxaliplatin, and
bevacizumab as first-line or second-line treatment for metastatic colorectal
cancer have resulted in median survival rates of about 18 months to 21 months
[3-8], but most patients eventually become chemo-refractory to these therapies
[8-9] and die of their disease [8-9].
The treatment of advanced metastatic colorectal cancer, which involves
conventional chemotherapy, is very costly and each year millions of dollars are
spent for treating patients with colorectal cancer in Canada [10-12], The rising
cost of treatment along with increasing rate of treatment failure is becoming a
significant financial burden on a publicly funded health-care system [10-11], The
current situation poses a great challenge for clinicians, researchers, and policy
makers to find new cost-effective ways for the treatment of advanced metastatic
colorectal cancer.
Epidermal growth factor receptor (EGFR) is a 170-kDa trans-membrane
tyrosine kinase receptor and belongs to human epidermal growth factor receptor
(HER) family [13], EGFR is present in most epithelial tissues and is widely
expressed in different types of cancer such as colorectal cancer, breast cancer,
stomach cancer and oesophageal cancer [13], The over expression EGFR is
associated with increased risk of cancer recurrence, metastasis and poorer
survival along with resistance to chemotherapy [13],
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According to recent research, the therapies targeting EGFR have shown
activity in chemorefractory metastatic colorectal cancer [8-9, 13-14] especially in
patients with the wild-type KRAS oncogene [13, 15-18], These therapies include
anti-EGFR monoclonal antibodies such as cetuximab (Erbitux®) and
panitumumab (Vectibix®). The anti-EGFR monoclonal antibodies specifically
bind to cysteine-rich extracellular domain of EGFR and compete with the other
natural ligands for binding to the receptor, thus preventing ligand-induced
activation of EGFR intracellular signalling pathway [13-18],
The KRAS gene plays an important role in the EGFR signalling pathway
and activating mutations in the KRAS gene are predictive of response to antiEGFR therapy in EGFR-expressing metastatic colorectal cancer [13-18], These
activating mutations lead to an independent and uncontrolled activation of
downstream EGFR intracellular signalling pathways which results in increased
tumour cell growth, proliferation, metastasis, protection against apoptosis, and
activation of tumour induced angiogenesis [13-19],
Both cetuximab and panitumumab are anti-EGFR monoclonal antibodies
[8-9] but they have significant structural differences. Cetuximab is a chimeric
monoclonal antibody with a significant amount of mouse protein [20-21], The
presence of this foreign protein increases the chance of antibody development
against the monoclonal antibody which also increases the chance of infusion
reactions [22], Panitumumab, on the other hand, is a fully humanized antibody [8,
23]; therefore, its use poses a low risk of anti-panitumumab antibody formation
and infusion reactions [22, 24-25],
Furthermore, cetuximab is an immunoglobulin G1 (lgG1) monoclonal
antibody [20-21], whereas panitumumab is an immunoglobulin G2 (lgG2)
monoclonal antibody [8, 21, 23], These differences are of clinical significance, as
dissimilar immunoglobulin subtypes affect complement activation and antibodymediated cytotoxicity differently [26],

3

In clinical practice, there is no therapeutic preference for using
cetuximab versus panitumumab either as immunotherapy or in combination with
chemotherapy as treatment of advanced metastatic colorectal cancer primarily
due to lack of trials directly comparing cetuximab versus panitumumab [21]. The
introduction of these new anti-EGFR therapies (panitumumab and cetuximab)
have shown to prolong the life of patients with advanced metastatic colorectal
cancer [8-9] but have also introduced a unique set of toxicities and increased
costs [8, 9, 27-30], In a shrinking health care resources environment, this
prompts the need for tools in form of economic analysis to identify the patients
who are likely to benefit from these therapies in a more efficient and costeffective way.
I developed an economic model using analytic decision modeling to
assess the cost-effectiveness of two anti-EGFR monoclonal antibodies
(cetuximab and panitumumab) plus best supportive care versus best supportive
care alone as third-line treatment in advanced chemorefractory metastatic
colorectal cancer patients. I also compared the cost-effectiveness of
panitumumab plus best supportive care versus cetuximab plus best supportive
care as third-line treatment using a cross-trial comparison method. Owing to the
importance of KRAS gene mutation in EGFR-expressing metastatic colorectal
cancer [13-19], I assessed the cost-effectiveness of KRAS testing by comparing
the cost and effectiveness both anti-EGFR therapies plus best supportive care
with and without KRAS testing.
The rationale for conducting a cost-effectiveness analysis using Markov
decision modeling is that it will offer an explicit and transparent approach to
quantify the costs and benefits of treatment strategies being compared by using a
common denominator i.e. quality-adjusted life years (QALYs). The resulting costutility ratios can then be compared across conditions with each other or with a
willingness-to-pay threshold value, with the goal of identifying the most efficient
ways of maximizing health at the population level. This approach has the
potential advantage of facilitating a deliberative, systematic, and data-driven
decision-making process for the allocation of public resources.
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The remainder of this thesis is organized as follows. In chapter 2 , 1have
discussed the literature review part of the thesis. In chapter 3, I have enumerated
the primary and secondary research questions related to the thesis. In chapter 4,
I have explained the materials and methods used to conduct my costeffectiveness analysis. In chapter 5, I have shown the results of my economic
analysis along with deterministic and probabilistic sensitivity analyses. I conclude
in chapter 6.
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Chapter 2: Literature Review
The first half of this chapter covers the biology and significance of KRAS
gene and epidermal growth factor receptor (EGFR) in advanced metastatic
colorectal cancer. Furthermore, it explains in detail the role of KRAS gene
mutations and response to anti-EGFR therapies in patients with advanced
metastatic colorectal cancer. The second half of the chapter describes different
types of economic analysis and decision analytic models used for health
economic evaluation.

2.1 Background / Biology & Significance of the KRAS gene
2.1.1 Location of the KRAS gene
The KRAS gene is also known as v-Ki-ras2 Kirsten rat sarcoma viral
oncogene homolog [31-32]. Its cytogenetic location is on the short arm (p) of
chromosome 12 at position 12.1 (12p12.1) and its molecular location is from
base pair 25, 249, 446 to base pair 25, 295, 120 on chromosome 12 [31-33],

2.1.2 Functions of the KRAS gene
The KRAS gene is a member of the RAS subfamily [31]. Like other
members of RAS subfamily such as HRAS and NRAS, it is involved in many
cellular signal transduction pathways such as the EGFR (epidermal growth factor
receptor) signalling cascade [17-18, 33-35], These signalling transduction
pathways are carried out through the KRAS protein encoded by the KRAS gene
and lead to important cell functions such as cell division, cell maturation, cell
differentiation and apoptosis (also known as the process of programmed cell
death “PCD”) [17-18, 33-35]. The KRAS protein is GTPase in nature and
converts GTP (Guanine Tri-Phosphate) to GDP (Guanine Di-Phosphate) by
cleaving the terminal phosphate of the nucleotide [18, 35].
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The binding of the KRAS protein to cell membranes occurs due to the
presence of an isoprenyl group on its C-terminus [13, 18]. The KRAS protein acts
like a control switch and it is activated by binding with GTP and deactivated when
GTP is converted to GDP [13, 18]. Once GTP is converted to GDP and the
KRAS is binded to GDP, it stops relaying any signals to the cell nucleus [13, 18].
2.1.3 Mutations in the KRAS gene
Somatic mutations in the KRAS gene play an important role in the
development of several types of cancer such as colorectal cancer [36],
pancreatic cancer [37] and lung cancer [38]. These activating point mutations
result from substitution of a single amino acid or single-nucleotide polymorphisms
(SNPs) such as p.Gly12Val in a critical part of oncogene structure known as
codons and leads to a block of the GTP hydrolytic activity of the K-ras-p21
protein [13, 18]. This results in a continuous activation of the KRAS protein and
this persistent activation of the KRAS protein is non-responsive to particular
regulatory signals from outside the cell and results in an uncontrolled and
continuous cell growth, cell proliferation and cell division [13, 18], About 90% of
activating mutations in the KRAS oncogene which are related to development of
different types of cancer especially colorectal cancer, occur in codons 12 (CGT)
and 13 (GGC) [13, 18]. According to recent studies some rare mutations also
occur at codons 61(CAA) and 146 [13, 17-18],

2.2 Background / Biology & Significance of the EGFR
2.2.1 EGFR (Epidermal growth factor receptor)
The EGFR (Epidermal growth factor receptor) is a 170-kDa trans
membrane tyrosine kinase receptor and belong to human epidermal growth
factor receptor (HER) family [13]. EGFR is present in most epithelial tissues and
is widely expressed in different types of cancer such as colorectal cancer, breast
cancer, stomach cancer and oesophageal cancer [13]. The over expression of
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EGFR is associated with increased risk of cancer recurrence, metastasis and
poorer survival along with resistance to chemotherapy [13].

2.2.2 Domains of the EGFR
Domains are the units of protein structure and sequence in a receptor
which can evolve, function, and exist independently of the rest of the protein
chain. Each domain forms a compact three-dimensional structure and may vary
in length from about 25 amino acids up to 500 amino acids [39]. The EGFR has
five domains.
1)

a cysteine-rich extracellular domain, which recognizes and binds

ligands such as epidermal growth factor (EGF), transforming growth factor
(TGF)-a and amphiregulin [39].
2)

a hydrophobic transmembrane domain, which is mainly involved

in interactions between cell surface receptors and plays an important role
in anchoring the receptor to the lipid bilayer of the cell [39].
3)

a tyrosine kinase domain, which can cross-phosphorylate

tyrosine residues of other receptors and plays an important role in
functional activation and induction of EGFR signalling pathways [39].
4)

an internalization domain, which regulates ligand internalization

and receptor sorting [39].
5)

a cytoplasmic domain also known as C-terminal domain, which

includes autophosphorylated tyrosine residues and plays an important role
in internal regulation of tyrosine kinase activity [13, 39].

2.2.3 Activation of the EGFR Signalling Pathway
The activation of EGFR signalling pathway occurs in a sequential manner.
In the first step, the binding of specific ligands to extracellular domain of EGFR
occurs, this results in the formation of a functionally active EGFR dimer (an
association of two identical molecules linked together) with another ligand-bound
EGFR or with one of the EGFR related receptors such as HER2 (human
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epidermal growth factor receptor 2), HER3 (human epidermal growth factor
receptor 3), or HER4 (human epidermal growth factor receptor4) [13, 40], Finally,
this receptor dimerization results in auto-phosphorylation of tyrosine kinase within
the C-terminal domain of the receptor which leads to the activation of several
downstream signalling cascades such as RAS-MAPK pathway, P13K-Akt
pathway and STAT pathway. These signal transduction pathways control gene
transcription, cell growth and proliferation, angiogenesis, and invasion [13, 40].
The KRAS gene plays an important role in the EGFR signalling pathway.
Activating mutations in the KRAS gene leads to an independent and uncontrolled
activation of downstream EGFR intracellular signalling pathways which results in
increased tumour cell growth, proliferation, invasion and activation of tumour
induced angiogenesis [13-19].

2.3 EGFR antagonists
Due to the important role of EGFR in cancer development and
progression, two types of EGFR antagonists have been developed to block the
downstream EGFR intracellular signalling which can potentially lead to inhibition
of tumour cell growth, proliferation and metastasis [13].
1)

The first type includes anti-EGFR monoclonal antibodies such as

cetuximab (Erbitux®) and panitumumab (Vectibix®). These anti-EGFR
antibodies specifically bind to Cysteine-rich extracellular domain of EGFR
and compete with other natural ligands for binding to the receptor, thus
preventing ligand-induced activation of EGFR intracellular signalling
pathway [13].
2)

The second type includes small-molecule EGFR-Tyrosine kinase

inhibitors such as gefitinib (Iressa®) and erlotinib (Tarceva®). These
EGFR-Tyrosine kinase inhibitors compete with ATP for binding to the
intracellular cytoplasmic domain also known as C-terminal domain of the
EGFR, thus inhibiting EGFR tyrosine phosphorylation [13]. This inhibition
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of EGFR tyrosine phosphorylation suppresses the activation of the
downstream EGFR intracellular signalling pathway [13].

2.4 EGFR gene mutations & Response to anti-EGFR therapy
The two types of EGFR antagonists such as anti-EGFR monoclonal
antibodies (cetuximab and panitumumab) and EGFR-Tyrosine kinase inhibitors
(gefitinib and erlotinib) have been evaluated extensively for the treatment of
different types tumours with EGFR over-expression [13, 34], These tumours
include colorectal cancer, metastatic non-small-cell lung cancer, squamous cell
carcinoma of the head and neck, and pancreatic cancer [13, 34],
The EGFR gene and the KRAS gene mutations generally occur
independently and are predictive of response to EGFR-targeted treatments
depending on the type of cancer [13]. The EGFR gene mutations are strongly
correlated with phosphorylation of the EGFR at tyrosine 992 (pEGFR-tyr992) and
are predictive of response to EGFR-Tyrosine kinase inhibitors (gefitinib and
erlotinib) in metastatic non-small-cell lung cancer [13, 41-43], Flowever, the
EGFR gene is rarely mutated (less than 1 %) in patients with colorectal cancer
and therefore it is a poor predictor of response to EGFR-targeted therapy in such
patients [13, 44],

2.5 KRAS gene mutations and response to anti-EGFR therapy
The KRAS gene mutation is predictive of response to EGFR-targeted
therapy in almost all EGFR-related cancers, particularly colorectal cancer and
non-small-cell lung cancer [13], The KRAS gene is mutated in approximately 30 40% of colorectal cancers [13], 20 - 30% of non-small-cell lung cancers [45], and
70 - 90% of pancreatic cancers [46], Recent studies have shown that advanced
metastatic colorectal cancer patients with the mutated KRAS gene respond
poorly to anti-EGFR monoclonal antibodies such as cetuximab and panitumumab
[13-19, 47], Similarly, studies evaluating the KRAS gene mutation status in non
small-cell lung cancer (NSCLC) patients have shown that mutations in the KRAS
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gene are strongly predictive of resistance to EGFR-Tyrosine kinase inhibitors
such as gefitinib and erlotinib [48-50],

2.6 Economic evaluation
Economic evaluation is defined as the comparative analysis of actions in
terms of both their costs and consequences in order to assist policy decisions
[51] . In the context of healthcare, the main purpose of economic evaluation is to
“identify, measure, value and compare the costs and health outcomes of
alternative treatment strategies being considered” [51] to inform “value for
money” judgments about a treatment strategy [52],
2.6.1 Stages of Economic Evaluation
The following are the main stages of an economic evaluation [51-52],
1.

Research Question

2.

Assessment of Costs and Consequences

3.

Analysis

4.

Variability and Uncertainty

2.6.2 Research Question
The first stage is to state the research question to be addressed by the
economic evaluation in a well defined and answerable form relevant to the
decision facing the target audience [52], The research question also defines the
target population in terms of their condition (e.g., stage or severity of the disease
or tumour) along with appraising the alternative treatment strategies
(comparators) relevant to the study [52], The primary perspective of the study
(e.g., public payer) and relevant secondary research questions are also defined
[52] ,
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2.6.3 Assessm ent of costs and consequences
The 2nd stage of an economic evaluation is the identification,
measurement and valuation of all type of costs and consequences (health
outcomes) related to the study with best available evidence and methods [51-52],
2.6.4 Analysis
The 3rd and most important stage of an economic evaluation is analysis.
The selection of appropriate type of analysis is entirely based on nature of the
research question, the condition of interest, and the availability of data on
outcomes [51-52], There are four main types of methods for economic evaluation
discussed below:
1.

Cost-effectiveness analysis (CEA)

2.

Cost-utility analysis (CUA)

3.

Cost-minimization analysis (CMA)

4.

Cost-benefit analysis (CBA)

2.6.5 Cost-effectiveness analysis (CEA)
According to the literature [52], the term “cost-effectiveness” is usually
used to refer to economic evaluations in general. In the context of healthcare, the
cost-effectiveness is a type of economic evaluation in which costs are expressed
in monetary terms and the health outcomes in natural health units such as lifeyears gained, adverse events avoided, and reduction in blood pressure etc [5152], The result of a cost-effectiveness analysis is expressed as incremental costeffectiveness ratio (ICER = incremental cost (CA - CB) / (EA-E B) incremental
effectiveness) [51-52], The net benefits approach may be used as an additional
measure to ICER especially when the incremental effectiveness is very small
(ICER becomes very large) and a willingness-to-pay threshold has been
assumed [52], The willingness-to-pay is defined as the maximum amount a
person would be willing to pay to acquire a good /service or to avoid an
undesired event [51],
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2.6.6 Cost-utility analysis (CUA)
Cost-utility analysis is based on the same principle as the costeffectiveness analysis [51]. Costs are measured in monetary terms and health
outcomes as health-related preferences (combined in to a weighted index;
valued as utilities) such as quality-adjusted life year (QALY) [51-52], Multiattribute utility instruments such as Health Utilities Index (HUI), Euroqol (EQ-5D),
and Quality of well-Being (QWB) are used to assign quality of life scores (utilities)
to health states [51].
Cost-utility analysis is method of choice when there are significant
differences in health-related quality of life (HRQoL) among treatment strategies
being compared [52], The use of a generic health outcome measure in a costutility analysis not only permits policy and decision makers to make broad
comparisons across treatment strategies but also facilitate the allocation of
resources based on maximizing health gains [52]. The result of a cost-utility
analysis is expressed as incremental cost-utility ratio (similar to ICER) [51-52].
The net benefits approach may be used as an additional measure to incremental
cost-utility ratio especially when the incremental effectiveness is very small
(incremental cost-utility ratio becomes very large) and a willingness-to-pay
threshold has been assumed [52],
2.6.7 Cost-minimization analysis (CMA)
Cost-minimization analysis is a type of economic study in which two or
more treatment strategies with same effectiveness or efficacy are compared in
terms of net costs in order to establish least costly alternative [51-52], In the
context of healthcare, a cost-minimization analysis can be regarded as an
extension of cost-utility or cost-effectiveness analysis, where the health
outcomes of treatment strategies being compared are demonstrated to be
equivalent in all aspects and only the costs of alternatives are being compared
[52].
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2.6.8 Cost-benefit analysis (CBA)
Cost-benefit analysis is a type of economic study where both costs and
consequences (health outcomes) are measured in monetary terms [51-52], In the
context of healthcare, the use of cost-benefit analysis in healthcare policy and
decision making is very limited due to methodological difficulties with measuring
health outcomes in monetary terms, and ethical issues arising from assigning
cost values to health outcomes [52],

2.6.9 Variability and uncertainty
This the final stage of economic analysis in which series of deterministic
and probabilistic sensitivity analyses are performed to verify the robustness of
results and to account for variability and uncertainty surrounding important
parameters in economic evaluation such as health outcomes, costs, probabilities,
timing and resource utilization [51-52],

2.7 Economic Evaluation Using Decision Analytic Modelling
Economic evaluation using decision analytic modelling is a logical
mathematical framework that permits the integration of a series of possible
consequences in the form of health and economic outcomes of patients that
would flow from the alternative courses of actions being evaluated [51],
In the context of health economic evaluation, decision analytic modeling
allows a rational, feasible, scientific, and timely approach to measure the
efficiency new medical interventions in health care by using the best available
evidence of various sources and produces detailed estimates of the clinical and
economic consequences [53],
The main purpose of economic evaluation using decision analytic
modelling is to structure all relevant evidence on clinical and economic outcomes
to help inform decisions about clinical practice and health-care resource
allocation under conditions of uncertainty, and to make these decision explicit
while considering the consequences of these decisions [51, 53],
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2.7.1 Stages in the development of decision analytic model
There are three main stages of development of a decision analytic model
[51]. First stage is to define the decision problem in terms of a research question
considering possible alternatives and payoffs [51,53]. The second stage is to
define model boundaries and parameters which include choice of perspective,
appropriate measures of cost and effectiveness, time horizon and various other
implications of intervention under consideration [51, 53]. The final stage is the
structuring of model based on timing of events, changes in probabilities,
extrapolation in to future and incorporation of all relevant costs and effects [51,
53],
2.7.2 Types of decision analytic models
There are three main types of decision analytic models [51]:
1.

Decision Tree

2.

Markov Model

3.

Microsimulation Model

2.7.3 Decision Tree
A decision tree uses a tree like graph or model of decisions and their
possible consequences [51]. The events are ordered from left to right and
different kinds of events are distinguished using three different shapes called
“nodes” [51].
•

Square

- a decision node indicating a choice and typically at

the start of the tree. The branches from a decision node represent the set
of alternative strategies being considered for evaluation [51].
•

Circle

- a chance node representing an event which has

multiple possible outcomes and is not under the decision maker’s control
[51, 53], The branches from a chance node represent the set of possible
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outcomes of the event which must be mutually exclusive and collectively
exhaustive [51]. The probabilities of these outcomes must sum to 1.0.
•

Triangle

- a terminal node which denotes the endpoint of a

scenario. A terminal node has no emanating branches and referred to
generically as payoff [51]. The payoff can be costs or effectiveness (LY’s
or QALYs) [51].
2.7.4 Markov Model
Markov models also known as state transition models are used for events
that occur repeatedly over time such as chronic or progressive diseases, cycles
of screening or treatment etc [51, 54], Markov models can handle both costs and
outcomes which make them a powerful tool for economic evaluation modeling
[51]. The main characteristics of a Markov model are shown below:
•

States - A Markov model consists of a set of mutually exclusive

states which must be defined. The states can be transient, temporary or
absorbing [51, 54],
•

Cycles - A Markov model is run for a fixed time period and is

broken up in to any number of cycles of fixed length (e.g., week, month,
and year) [51]. At the end of each cycle, patients either remain in the
same state or move in to a new state and then start over again in a new
cycle [51, 54],
•

Transition probabilities - A Markov model consists of a set of

transition probabilities among states which determine the % of members
of state that transition to different states to start the next cycle [51, 54],
The state transition probabilities can be constant or time-dependent [51,
54],
•

Rewards - The patients in each state accumulate rewards (e.g.,

costs, utilities, event counts) at every cycle or at specific transitions
defined in the model [51, 54],
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2.7.5 Microsimulation Model
Microsimulation models are based on Monte Carlo simulation technique
that generates individual patient histories [51]. A set of rules (transition
probabilities) are applied to individual patients leading to simulated changes in
state and behaviour [51]. The rules can be deterministic (probability = 1) or
stochastic (probability < = 1). Individual patients (trials) randomly walk through
the model and generate individual outcomes [51]. By analyzing the aggregate
results for a set of trials, not only the expected value can be estimated but also
the variability among individual outcomes can be examined [51, 54],
In contrast to standard Markov cohort analysis where expected valued is
based on entire cohort, the Microsimulation model generates individual outcomes
(cost and effectiveness) for individual patients (trials) based on each random
walk [51]. Microsimulation models can be used to track individual patient
characteristics (e.g., Age, gender, tumour type, tumour size etc) and individual
patient events (e.g., number of adverse events, apply chemotherapy treatment
etc) [51]. A standard Markov cohort analysis cannot account for such individual
patient characteristics because cohort is homogenous [51]. Microsimulation
models are expensive to build and rely on heavily comprehensive databases and
sometimes it is difficult to interpret the simulation results.
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Chapter 3: Research Questions

3.1 Primary research question
To assess the cost-effectiveness of adding the anti-EGFR monoclonal
antibodies (cetuximab and panitumumab) to best supportive care as third-line
therapy in treatment of advanced metastatic chemo-refractory colorectal cancer.

3.2 Secondary research questions
1. To analyze the effect of KRAS gene mutation status on the costeffectiveness of cetuximab and panitumumab as third-line therapy in
treatment of advanced metastatic colorectal cancer.
2. To analyze the cost-effectiveness of KRAS gene testing prior to treatment
with cetuximab and panitumumab as third-line therapy in treatment of
advanced metastatic colorectal cancer.
3. To evaluate the cost-effectiveness of anti-EGFR therapies (cetuximab and
panitumumab) plus best supportive care at various willingness-to-pay
threshold values.
4. To determine the sensitivity of primary model output (incremental costutility ratio) to various parameters in the economic model.
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Chapter 4: Materials & Methods
I developed an economic model using Markov decision modeling to assess:
1.

The cost-effectiveness of two anti-EGFR monoclonal antibodies

(cetuximab and panitumumab) plus best supportive care versus best
supportive care alone as third-line treatment in advanced chemorefractory
metastatic colorectal cancer patients.
2.

The cost-effectiveness of KRAS testing by comparing the cost and

effectiveness of both anti-EGFR therapies (cetuximab and panitumumab)
plus best supportive care with and without KRAS testing.
I used the efficacy data from two multi-center clinical trials for my costeffectiveness analysis. The first study, NCIC CTG (National Cancer Institute of
Canada Clinical Trials Group) CO. 17 trial compared the efficacy of cetuximab
plus best supportive care versus best supportive care alone as third line
treatment of patients with advanced metastatic colorectal cancer [9, 16]. The
second study, Open-Label Phase III trial compared the efficacy of panitumumab
plus best supportive care versus best supportive care alone as third line
treatment of patients with advanced metastatic colorectal cancer [8, 15].
I also compared the cost-effectiveness of cetuximab plus best supportive
care versus panitumumab plus best supportive care as third-line treatment using
a cross-trial comparison method. This is an indirect comparison owing to the
absence of a direct head to head trial of cetuximab plus best supportive care
versus panitumumab plus best supportive care as third-line treatment in
advanced metastatic colorectal cancer patients.
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4.1 Patient characteristics in clinical trial studies
The demographics and baseline characteristics of the patients were quite
similar across both studies [8, 9], as shown in Table 4.1. Eligible patients in both
studies had advanced metastatic colorectal cancer expressing epidermal growth
factor receptor (EGFR) which was refractory to all recommended chemotherapy
and detectable by immunohistochemistry [8, 9].
The patients in both trials had an ECOG (Eastern Cooperative Oncology
Group) performance status of 0 to 2 and the random assignment of patients in to
treatment (anti-EGFR therapy plus best supportive care) and control (best
supportive care alone) groups was stratified by ECOG performance status (0 or 1
vs. 2) [8, 9], The ECOG performance status is a measure of how well a patient is
able to carry on ordinary daily activities while living with cancer [55]. The ECOG
performance status is ranged from 0 to 5 with 0 being the best scenario (Fully
active, able to carry on all pre-disease performance without restriction) and 5
being the worst scenario (dead) [55]. The ECOG performance status is widely
used in oncology practice because of its correlation with patient survival duration
and response to treatment, as well as their quality of life and co-morbidity [55],
The ECOG performance status scoring system is also used to decide which
patients are physically suitable for treatment or entry into a clinical trial [55],
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Table 4.1. Demographics and Baseline characteristics of the patients

Open-Label Phase III Trial

NCIC CTG - CO. 17 Trial
Characteristic

Cetuximab + BSC

BSC Alone

Panitumumab + BSC

BSC Alone

(N=287)

(N=285)

(N=231)

(N=232)

No.

%

No.

%

No.

%

No.

%

Age, years

Median
Range

63

63.6

62

63

28.6-88.1

28.7-85.9

27.0-82.0

27.0-83.0

Sex

Male

186

64.8

182

63.9

146

63

148

64

Female

101

35.2

103

36.1

85

37

84

36

ECOG performance status

0

72

25.1

64

22.5

107

46

80

34

1

148

51.6

154

54

94

41

115

50

2

67

23.3

67

23.5

29

13

35

16

103

36.1

86

37

78

34

Previous adjuvant chemotherapy

108

37.6

Abbreviations: NCIC CTG (National Cancer Institute of Canada Clinical Trials Group), BSC (Best Supportive Care), ECOG
(Eastern Cooperative Oncology Group).

4.2 Structure of the Markov model
Three separate Markov models were developed to achieve the primary
and secondary objectives of the economic analysis. The Markov models were
constructed using TreeAge Pro Suite 2009 (TreeAge Software Inc.,
Williamstown, MA). The Markov models consist of three mutually exclusive
health states with state transitions at the end of each model cycle.
1.

progression free

2.

progression

3.

death
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The Markov model 1 was developed to evaluate the cost-effectives
of anti-EGFR therapies (panitumumab and cetuximab) plus best supportive care
versus best supportive care alone without KRAS testing prior to treatment. The
patient population was distributed in to treatment arms based on the population
distribution of KRAS gene mutation status (as shown in Figure 4.1). I assumed a
population distribution for KRAS mutation status as 60% KRAS wild-type and
40% mutant-type KRAS based on evidence from literature [13-18].
The Markov model 2 was developed to evaluate the cost-effectiveness of
KRAS testing by comparing the cost and effectiveness of anti-EGFR therapies
(panitumumab and cetuximab) plus best supportive care with and without KRAS
testing. The patient population was distributed in to treatment arms based on the
sensitivity and specificity of KRAS testing (as shown in Figure 4.2). In both trial
studies, real-time PCR (polymerase chain reaction) technology (DxS
TheraScreen™ kit in Open-Label Phase III trial and QIAamp DNA Mini Kit in CO.
17 trial) [15, 16], was used to detect KRAS mutation status with a validated
sensitivity of 0.95 and specificity of 1.0 [56-58].
The Markov model 3 was developed to evaluate the cost-effectiveness of
anti-EGFR therapies (panitumumab and cetuximab) plus best supportive care in
subset of patients with wild-type KRAS gene only (as shown in Figure 4.3).
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Figure 4.1. Markov model 1
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Figure 4.2. Markov model 2
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Figure 4.3. Markov model 3
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The progression-free state is the entry state of the model and includes
patients with stable or partially responsive disease. All patients were assumed to
be in progression-free state at cycle 0 (first cycle) of the model. Death is the
terminal or absorbing state of my Markov model. The selection of health states
was based on actual health states observed in both trials and type of response to
the treatment [8-9],
The Markov models had a Markov termination condition of two years with
52 cycles. Each cycle length was two weeks to match the duration of treatment
cycles in both trial studies. The Markov termination condition was based on
maximum time of follow up in both trial studies. The maximum time of follow-up
was 1.58 years (median follow-up time = 70.4 weeks) for the CO. 17 trial and 1.9
years (median follow-up = 72 weeks) for the Open-Label Phase III trial [8-9],
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4.3 Response rates
In the CO. 17 trial, 8% of the patients receiving cetuximab plus best
supportive care showed partial response to the treatment as compared to none in
patients receiving best supportive care alone [9], The stable disease was
observed in 31.4% of the patients receiving cetuximab plus best supportive care
as compared to 10.9% in patients receiving best supportive care alone [9].
Objective progression of the disease was observed in 78.04% of the patients in
cetuximab plus best supportive care group as compared to 62.4% in best
supportive care alone group [9],
In KRAS assessable group, 12.8% of the patients with wild-type KRAS in
cetuximab plus best supportive care group had partial response to treatment as
compared to 1.2% in patients with mutated KRAS gene [16]. A total of 222
(77.35%) deaths occurred in cetuximab plus best supportive care group and 234
(82.1%) deaths in best supportive care only group [9], Almost all deaths in the
study were related to disease progression (450 out of 456 deaths) [9],
In the Open-Label Phase III trial, 10% of the patients in panitumumab plus
best supportive care group showed partial response to the treatment as
compared to none in best supportive care alone group [8]. The stable disease
was observed in 27% of the patients in panitumumab plus best supportive care
group as compared to 10% in best supportive care alone group [8]. Objective
progression of the disease was observed in 75% of the patients in panitumumab
plus best supportive care group as compared to 85% in best supportive care
alone group [8],
In KRAS assessable group, 17% of the patients with wild-type KRAS in
panitumumab plus best supportive care group had partial response to treatment
as compared to none in patients with mutated KRAS gene [15]. A total of 186
(81%) deaths occurred in panitumumab plus best supportive care group and 194
(84%) deaths in best supportive care only group [8], Almost all deaths in the
study were related to disease progression [8],
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4.4 Markov model probabilities
The Markov state transition probabilities were derived from progressionfree survival (PFS) and overall survival (OS) Kaplan-Meier plots. In both studies
time-to-event variables (progression-free survival and overall survival) were
summarized using Kaplan-Meier plots [8-9, 15-16],
Based on the cycle length of the Markov model, the probability value for
progression-free survival (PFS) and overall survival (OS) was calculated at each
following two weeks from Kaplan-Meier plots until the end point of 104 weeks (52
cycles, 2 years) was reached. For progression-free survival (PFS) and overall
survival (OS) Kaplan-Meier plots where maximum follow-up was less than 104
weeks (2 years), the last probability value recorded at the end of follow-up period
was carried forward. The state transition probabilities were derived separately for
wild-type KRAS and mutant-type KRAS in each treatment group.

4.4.1 Markov state transition probabilities for anti-EGFR therapies
plus best supportive care
The transition probabilities from the progression-free state to progression
and from the progression state to death at the end of each Markov cycle were
derived using the progression-free survival (PFS) and the overall survival (OS)
Kaplan-Meier plots for wild-type KRAS and mutant-type KRAS in each trial study
[15, 16]. Though most of the deaths in both trials were related to disease
progression [8-9, 15-16], there were some deaths due to causes other than
disease progression. Therefore, to derive the Markov state transition probabilities
from the progression-free state to death, I used annual mortality rates from
Canadian life tables for particular mean age in each treatment group [59].
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4.4.2 Markov state transition probabilities for best supportive care
alone
To derive the state transition probabilities for best supportive care alone
arm in my Markov model, I combined the data from the progression-free survival
(PFS) and the overall survival (OS) Kaplan-Meier plots for wild-type KRAS and
mutant-type KRAS in best supportive care alone group from both trials to get
averaged progression-free survival (PFS) and overall survival (OS) Kaplan-Meier
plots [15, 16], as shown in Figure 4.4 and Figure 4.5.
The state transition probabilities from the progression-free state to
progression and from the progression state to death at the end of each Markov
cycle were calculated using averaged progression-free survival (PFS) and
averaged overall survival (OS) Kaplan-Meier plots for wild-type KRAS and
mutant-type KRAS in best supportive care alone group. The Markov state
transition probabilities from the progression-free state to death were calculated
using annual mortality rates from Canadian life tables for particular mean age in
best supportive care alone group [59].
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Figure 4.4. Averaged progression-free Survival (PFS) Kaplan-Meier plot for best
supportive care alone (BSC Alone), upper graph - 4.4a (wild - type KRAS), lower graph 4.4b (mutant - type KRAS).
Figure 4.4a
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Figure 4.4b
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Figure 4.5. Averaged overall survival (OS) Kaplan-Meier plot for best supportive care alone
(BSC Alone), upper graph - 4.5a (wild - type KRAS), lower graph - 4.5b (mutant - type
KRAS).
Figure 4.5a

Figure 4.5b
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4.5 Validation of the Markov model
The fit and accuracy of the Markov model was ascertained by comparing
the probability values for progression-free survival, progression and death
produced by the Markov model with the probability values obtained from trial
studies, as shown in Figure 4.6 to Figure 4.11.

Figure 4.6. Comparison of progression-free survival (4.6a), death (4.6b) and progression
(4.6c) probabilities Kaplan - Meier plots obtained from the Markov model output and from
the trial studies (CO.17 & Open Label phase III trial) for best supportive care alone (mutanttype KRAS).
Figure 4.6a
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Figure 4.6c

Figure 4.7. Comparison of progression-free survival (4.7a), death (4.7b) and progression
(4.7c) probabilities Kaplan - Meier plots obtained from the Markov model output and from
the trial studies (CO.17 & Open Label phase 111 trial) for best supportive care alone (wild-type
KRAS).
Figure 4.7a

Markov Model
— — Trial Study

Time since Randomization (weeks)

32

Figure 4.7b

Figure 4.7c
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Figure 4.8. Comparison of progression-free survival (4.8a], death (4.8b) and progression
(4.8c) probabilities Kaplan - Meier plots obtained from the Markov model output and from
the trial study (CO.17 trial) for cetuximab plus best supportive care (mutant-type KRAS).
Figure 4.8a
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Figure 4.8c
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Figure 4.9. Comparison of progression-free survival (4.9a), death (4.9b) and progression
(4.9c) probabilities Kaplan - Meier plots obtained from the Markov model output and from
the trial study (CO.17 trial) for cetuximab plus best supportive care (wild-type KRAS).
Figure 4.9a
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Figure 4.9 b

Figure 4.9c
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Figure 4.10. Comparison of progression-free survival (4.10a), death (4.10b) and
progression (4.10c) probabilities Kaplan - Meier plots obtained from the Markov model
output and from the trial study (Open Label phase III trial) for panitumumab plus best
supportive care (mutant-type KRAS],
Figure 4.10a
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Figure 4.10c

Figure 4.11. Comparison of progression-free survival (4.11a), death (4.11b) and
progression (4.11c) probabilities Kaplan - Meier plots obtained from the Markov model
output and from the trial study (Open Label phase III trial) for panitumumab plus best
supportive care (wild-type KRAS).
Figure 4.11a
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Figure 4.11b

Figure 4.11c

4.6 Health utilities
The health utility values used in the model were obtained from the
literature [60-63] (shown in Table 4.2). The health utility values were varied by +/20% of the original base case value for the purpose of various sensitivity
analyses.
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Table 4.2. Health utility values for different health states used in the Markov model

Treatment strategy

Health state

Base Case
Value *

Progression Free*

0.80

Progression

0.69

Progression Free*

0.73

Progression

0.72

Source

P an itu m u m ab + BSC

C Graham et al. Annals of Oncology 2008;
ISSN 0923-7534, [61]
C Graham et al. Annals of Oncology 2008;
ISSN 0923-7534, [61]

C etu xim ab + BSC

N Mittmann et al, J Natl Cancer Inst 2009;
101:1182-1192, [60]
N Mittmann et al, J Natl Cancer Inst 2009;
101:1182-1192, [60]

BSC A lo n e +
(A veraged)

Progression Free*

0.715

Progression

0.65

Progression Free*

0.68

Progression

0.63

Progression Free*

0.75

Progression

0.67

C Graham et al. Annals of Oncology 2008;
ISSN 0923-7534, [61]
N Mittmann et al, J Natl Cancer Inst 2009;
101:1182-1192, [60]
C Graham et al. Annals of Oncology 2008;
ISSN 0923-7534, [61]
N Mittmann et al, J Natl Cancer Inst 2009;
101:1182-1192, [60]

B SC A lo n e
(N C IC C T G C O .17
trial)

N Mittmann et al, J Natl Cancer Inst 2009;
101:1182-1192, [60]
N Mittmann et al, J Natl Cancer Inst 2009;
101:1182-1192, [60]

BSC A lo n e
(OL Ph ase 111 trial)

C Graham et al. Annals of Oncology 2008;
ISSN 0923-7534, [61]
C Graham et al. Annals of Oncology 2008;
ISSN 0923-7534, [61]

*Progression-free State includes patients with stable or partially responsive disease.
yp Base case values represent the average health utility value for a particular health state adjusted for treatment
related toxicity.
+ The base case values for best supportive care alone group represents the averaged health utility values for
progression free and progression state obtained from both trial studies.
BSC = best supportive care, NCIC CTG = National Cancer Institute of Canada Clinical Trials Group.
OL Phase III = Open Label Phase III study
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4.7 Costs
Costs were estimated using the perspective of a public payer (the Ontario
Ministry of Health and Long-Term Care). Only direct medical costs were included
in the model and are presented in 2010 Canadian dollars (Can $1 = US $1).
Costs that were not available in 2010 Canadian dollars were adjusted for inflation
by using consumer price index (Healthcare - Ontario) Statistics Canada [64],
Indirect medical costs were not estimated as they are irrelevant for the chosen
perspective [60],

4.7.1 Direct Medical Costs
Direct medical costs used in the model include best supportive care costs,
drug cost of anti-EGFR monoclonal antibodies (cetuximab and panitumumab),
cost of KRAS testing and cost of management of adverse events. Best
supportive care costs includes the cost of outpatient physician visits, laboratory
tests, hospitalization, emergency department visits, blood transfusions,
concomitant medications, blood products and Imaging.
These costs were obtained from the literature [60] and adjusted for
consumer price index (CPI -2010) [64], I used a cost value of $452 per patient for
KRAS testing [57], Best supportive care costs were assumed to be same for both
anti-EGFR therapies (cetuximab and panitumumab). The best supportive care
alone (BSC alone) costs and best supportive care costs in combination with antiEGFR therapy are shown in Table 4.3 and Table 4.4 respectively.
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Table 4.3. Best supportive care alone costs

Components

Base case value*

Source

(Bi-weekly)

Outpatient Physician Visits

8.864

N Mittmann et al, J Natl Cancer Inst 2009;101:1182-1192, [60]

Laboratory tests

0.701

N Mittmann et al, J Natl Cancer Inst 2009;101:1182-1192, [60]

Hospitalization

75.04

N Mittmann et al, J Natl Cancer Inst 2009;101:1182-1192, [60]

Concomitant Medications

2.694

N Mittmann et al, J Natl Cancer Inst 2009;101:1182-1192, [60]

Blood Products

5.416

N Mittmann et al, J Natl Cancer Inst 2009;101:1182-1192, [60]

Imaging

1.939

N Mittmann et al, J Natl Cancer Inst 2009;101:1182-1192, [60]

Other costs¥

9.026

N Mittmann et al, J Natl Cancer Inst 2009;101:1182-1192, [60]

Total BSC alone cost+

103.682

* Base case value represents cost per patient every 2 weeks and adjusted for consumer price index- 2010.
¥ Other costs include cost of emergency room visits and blood transfusions.
t Total BSC alone costs represent the total best supportive care alone cost per patient every two weeks used in the
Markov model.
BSC = Best supportive care, All costs are presented in 2010 Canadian dollars.

Table 4.4. Best supportive care costs in combination with anti-EGFR therapy

Components

Base case value*

Source

(Bi-Weekly)

Outpatient Physician Visits

12.044

N Mittmann et al, J Natl Cancer Inst 2009;101:1182-1192, [60]

Laboratory tests

9.188

N Mittmann et al, J Natl Cancer Inst 2009;101:1182-1192, [60]

102.469

N Mittmann et al, J Natl Cancer Inst 2009;101:1182-1192, [60]

Concomitant Medications

2.694

N Mittmann et al, J Natl Cancer Inst 2009;101:1182-1192, [60]

Blood Products

4.392

N Mittmann et al, J Natl Cancer Inst 2009;101:1182-1192, [60]

Imaging

8.137

N Mittmann et al, J Natl Cancer Inst 2009;101:1182-1192, [60]

Other costs v

10.562

N Mittmann et al, J Natl Cancer Inst 2009;101:1182-1192, [60]

Total BSC Costst

149.487

Hospitalization

* Base case value represents cost per patient every 2 weeks and adjusted for consumer price index- 2010
^ other costs include cost of emergency room visits and blood transfusions.
+ It represents total best supportive care (in combination with anti-EGFR therapy) cost per patient every two weeks
used in the Markov model, BSC = Best supportive care, All costs are presented in 2010 Canadian dollars.
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4.8 Drug costs
4.8.1 Drug cost of cetuximab
In the NCIC CTG (National Cancer Institute of Canada Clinical Trials
Group) CO. 17 trial study [9], the patients in cetuximab plus best supportive care
group received an initial dose of cetuximab as 400 mg / m2 (body surface area)
given intravenously over a period of 120 minutes [9]. The initial dose was
followed up by weekly maintenance dose of 250 mg /m2 given intravenously over
a period of 60 minutes [9]. The weekly maintenance dose was continued until
disease progression [9].
A cost of $345 for 100 mg / 5ml single use vial of cetuximab was obtained
from London Health Sciences Center (LHSC) drug formulary intranet. The cost
estimation for total dose of cetuximab given to each patient is based on average
healthy male with a body weight of 70 kg and body surface area of 1.7 m2 [65,
66]. For the initial dose of cetuximab i.e. 400 mg / m2, the estimated total dose is
680mg (400mg x 1.7 (body surface area) = 680mg) or 7 single-use vials of
cetuximab. The estimated total cost for initial dose of cetuximab is $2,415 per
patient. For the weekly maintenance dose of cetuximab i.e. 250 mg / m2, the
estimated total dose is 425mg (250mg x 1.7 (body surface area) = 425mg) or 5
single-use vials of cetuximab. The estimated total cost of weekly maintenance
dose of cetuximab is $1,725 per patient (Table 4.5).
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Table 4.5. Drug cost of cetuximab and source information

Variable

Cost (Can $)

Source

Cost of 100 mg/5ml single use vial

345

LHSC drug formulary intranet - 2010

Cost of Initial dose of 400 mg /m2

2415

(680mg - 7 Vials)t
Cost of weekly maintenance dose of 250 mg/m2

1725

(425mg - 5 Vials)+
Administration cost / hr (adjusted for CPI -2010)

108.91

Calculated (see text)

Calculated (see text)
N Mittmann et al, J Natl Cancer Inst 2009;
101:1182-1192, [60]

4466.72
Total Cost / patient for the first 2 weeks*
3667.82
Total Cost / patient for every following 2 weeks*

Calculated (see text)

Calculated (see text)

+ Based on average healthy male with a body weight of 70kg & body surface area of 1.7m2 (initial dose= 400 x 1.7 =
680 mg, maintenance dose= 250 x 1.7 = 425mg)
♦ First 2 weeks includes the cost of initial dose (400 mg/m2) plus the cost of weekly maintenance dose (250 mg/m2)
along with 3 hours of administration cost (2 hrs for initial dose plus 1 hr for maintenance dose)
♦ Every following 2 weeks includes cost of two maintenance doses along with 2 hrs of administration cost
CPI = consumer price index, LHSC = London Health Sciences Center, All costs are presented in 2010 Canadian dollars.

4.8.2 Drug cost of panitumumab
In the Open-Label Phase III trial study, the patients in panitumumab plus
best supportive care group received a bi-weekly dose of panitumumab as 6mg /
kg (body weight) given intravenously over a period of 60 minutes [8]. The bi
weekly maintenance dose was continued until disease progression [8], A cost of
$650 for 100 mg /5ml single use vial of panitumumab was obtained from London
Health Sciences Center (LHSC) drug formulary intranet. The cost estimation for
total dose of panitumumab given to each patient bi-weekly is based on average
healthy male with a body weight of 70 kg [65, 66], For bi-weekly dose of
panitumumab i.e. 6mg / kg, the estimated total dose is 420mg (6mg x 70 (body
weight) = 420mg) or 5 single-use vials of panitumumab. The estimated total cost
for bi-weekly dose of panitumumab is $3,250 per patient (Table 4.6).

44
Table 4.6. Drug cost of panitumumab and source information

Variable

Cost (Can $)

Cost of 100 mg/5ml single use vial
Cost of Bi-Weekly dose of 6 mg /kg

650

3250

(420mg - 5 Vials)+
Administration cost / hr

108.91

LHSC drug formulary intranet - 2010

Calculated (see text)
N Mittmann et al, J Natl Cancer Inst 2009;
101:1182-1192, [60]

(adjusted for CPI -2010)
Total Cost / patient for every 2 weeks*

Source

3358.91

+ Based on average healthy male with a body weight of 70kg (6 x 70 = 420mg or 5 single use vials)
*Every 2 weeks includes cost of Bi-weekly dose of 6mg/kg along with 1 hr (60 minutes) of administration cost
CPI = consumer price index, LHSC = London Health Sciences Center, All costs are presented in 2010 Canadian dollars.

4.9 Cost of Adverse Events
Only the costs for the management of grade 3 and 4 adverse events were
included in the model because the costs for the management of less severe
adverse events would not be associated with any substantial health-care
resources consumption and economically not relevant [60, 61]. The cost
estimation was done for grade 3 or 4 skin toxicity, infusion reaction,
hypomagnesaemia, non-neutropenic infection and other pain (Table 4.7). These
adverse events were significantly different among the treatment groups in both
trial studies [8, 9]. Grade 3 or 4 toxicity profile for each treatment strategy is
shown in Table 4.8. The other pain category excludes myalgia, earache,
headache and abdominal, bone, chest, hepatic, neuropathic, pelvic, pleuritic,
rectal, perirectal, and tumour pain [9, 60],
The cost estimation for management of toxicity was based on treatment
protocols for each grade 3 or 4 adverse event obtained from existing literature
[27-30] and expert opinion. The total cost per patient represents the costs for the
management of an incident case of grade 3 or 4 adverse for entire model length
(Table 4.7).
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Table 4.7. Treatment cost of grade 3 and 4 adverse events

Type of Toxicity (only grade 3 and 4)

Cost (Can $)

Source

Skin Toxicity

Cost per patient for the first month
(Including physician visit)
Cost per patient for every month afterwards

199
56

London Regional cancer program- 2010

London Regional cancer program- 2010

Infusion reactions

Average cost per stay for Infusion reaction

Average cost per ER visit

Total cost per patient*

7263.09

268.38

The cost of acute care Hospital stays by Medical
condition in Canada , 2004 - 2005, CIHI
The average cost of an ED visit in 2007-2008,
CIHI

7531.47

H ypom agnesaem ia

Magnesium sulfate 5 g / 10 ml Injection
3-times weekly IV infusion of Magnesium
sulfate at 10g per dose

0.75

LHSC drug formulary intranet - 2010

4.5

N o n -n eu tro p en ic infection

Total cost per patient*

2458.95

N Mittmann et al, J Natl Cancer Inst 2009;
101:1182-1192, [60]

P a in t

Total cost per patient*

28.37

N Mittmann et al, J Natl Cancer Inst 2009;
101:1182-1192, [60]

*Total cost per patient represent cost for treating one incident case of grade 3 or 4 adverse event and cost adjusted
for consumer price index -2010, where applicable.
+ It excludes arthralgia, myalgia, earache, headache and abdominal, bone, chest, hepatic, neuropathic, pelvic,
pleuritic, rectal, perirectal, and tumour pain.
ER visit = Emergency room visit, IV infusion = Intravenous infusion, LHSC = London Health Sciences Center, CIHI =
Canadian Institute for Health Information, All costs are presented in 2010 Canadian dollars.
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Table 4.8. Grade 3 or 4 toxicity profile for each treatment strategy & source information

Type of Toxicity
(Grade 3 or 4)

Patients with grade
3 or 4 adverse

Toxicity due to BSC Alone
Skin toxicity
Non-neutropenic
infection
Pain

Source

events

*

0.40 %

5.50 %

Derek J. Jonker et al.(2007), N Engl J Med 2007;357:2040-8; [16]
Eric Van Cutsem et al. DOI:10.1200/JCO.2006.08.1620, [15]
Derek J. Jonker et al.(2007), N Engl J Med 2007;357:2040-8; [16]
Eric Van Cutsem et al. DOI:10.1200/JCO.2006.08.1620, [15]
Derek J. Jonker et al.(2007), N Engl J Med 2007;357:2040-8; [16]

7.30 %

Eric Van Cutsem et al. DOI:10.1200/JC0.2006.08.1620, [15]

Toxicity due to Cetuxim abf
Skin toxicity

11.40 %

Derek J. Jonker et al.(2007), N Engl J Med 2007;357:2040-8, [16]

Infusion reaction

4.50 %

Derek J. Jonker et al.(2007), N Engl J Med 2007;357:2040-8, [16]

Hypomagnesaemia

5.80 %

Derek J. Jonker et al.(2007), N Engl J Med 2007;357:2040-8, [16]

Non-neutropenic
infection
Pain

7.30 %
7.60 %

Derek J. Jonker et al.(2007), N Engl J Med 2007;357:2040-8, [16]

Derek J. Jonker et al.(2007), N Engl J Med 2007;357:2040-8, [16]

Toxicity due to Panitumumab ^
Skin toxicity

11.60%

Eric Van Cutsem et al. DOI:10.1200/JC0.2006.08.1620, [15]

Infusion reaction

0.43 %

Eric Van Cutsem et al. DOLIO.1200/JCO.2006.08.1620, [15]

Hypomagnesaemia

3.0 %

Eric Van Cutsem et al. DOLIO.1200/JCO.2006.08.1620, [15]

¥ Toxicity profile (grade 3 or 4 adverse events) for best supportive care alone (BSC alone) obtained from CO.17 trial
and Open-Label phase III trial.
t Toxicity profile (grade 3 or 4 adverse events) for cetuximab only, after adjusting for toxicity due to best supportive
care.
Y Toxicity profile (grade 3 or 4 adverse events) for panitumumab only, after adjusting for toxicity due to best
supportive care.
AE = Adverse Events.
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4.10 Discounting
In Canada a discount rate of 5% is used for economic analysis [67],
therefore the incremental cost-utility ratios presented in my model were
discounted at a rate of 5% using TreeAge Pro Suite 2009 (TreeAge Software
Inc., Williamstown, MA). However, it is important to note that, given the median
survival of less than a year for patients in both trial studies [8, 9], it is unlikely that
discounting would have a large impact on model outcome.

4.11 Sensitivity analyses
I performed a series of deterministic and probabilistic sensitivity analyses
using TreeAge Pro Suite 2009 (TreeAge Software Inc., Williamstown, MA) to test
the robustness of the key model output (incremental cost-utility ratios), and to
handle uncertainty in model parameters.
4.11.1 Deterministic sensitivity analyses
The one-way deterministic sensitivity analyses were carried out to
estimate the effect of variation in all model parameters on model outcome. The
parameter values above or below which each treatment strategy became costeffective were recorded. An additional univariate sensitivity analysis was also
conducted by changing the values of key model parameters such as best
supportive care costs, drug costs, cost of toxicity, health utility values and cost of
KRAS testing by + /- 20 % of the original base case values to determine which
variables have the greatest influence on the results of the model. I also carried
out one-way deterministic sensitivity analysis on sensitivity and specificity of
KRAS testing. For sensitivity analysis purpose the sensitivity of KRAS testing
was varied from 0.92 to 0.98 and specificity was varied from 0.95 to 1.0.
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4.11.2 Probabilistic sensitivity analysis
The probabilistic sensitivity analysis was performed with 1,000 Monte
Carlo simulations using distributions for all key model parameters such as
various model costs, state transition probabilities and health utility values. I used
normal distributions for all types of costs in the Markov model with base case
values serving as the mean and the standard deviations calculated from high and
low ranges derived from +/- 20% change in base case values. The uniform
distributions were used for health utility values with high and low values
calculated from +/- 20% change in base case values. The uniform multiplier
method was used to account for variability in state transition probabilities and the
new distribution tables for state transition probabilities were directly input in the
Markov model.
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Chapter 5: Results
5.1 Cost-effectiveness of anti-EGFR therapies (No KRAS testing)
I first evaluated the incremental cost-effectiveness of both anti-EGFR
therapies (cetuximab and panitumumab) plus best supportive care versus best
supportive care alone without KRAS testing (Table 5.1). Compared to best
supportive care alone, the incremental cost per patient for panitumumab plus
best supportive is $29,622. The panitumumab plus best supportive care resulted
in a mean gain of 0.07 QALYs, with a mean incremental cost utility ratio of
$419,528 per QALY gained. Compared to cetuximab plus best supportive care,
the panitumumab plus best supportive care resulted in a mean gain of 0.0118
QALYs with an incremental cost of - $3,852 per patient. My base case costeffectiveness analysis showed that treatment strategy “cetuximab plus best
supportive care” is dominated by treatment strategy “panitumumab plus best
supportive care” (Figure 5.1).

Table 5.1. Incremental cost-effectiveness of anti-EGFR therapies (cetuximab and
panitumumab) without KRAS testing (Markov model 1).
Treatment
strategy

Cost per
patient

Incremental
cost per patient

Effectiveness
per patient
(QALYs)

Incremental
effectiveness per
patient (QALYs)

ICER

0.4017

BSC Alone

$1,649

Panitumumab
plus BSC

$31,271

$29,622

0.4723

0.0706

$419,528

Cetuximab
plus BSC

$35,123

$3,852

0.4604

-0.0118

Dominated

EGFR = Epidermal growth factor receptor, BSC = best supportive care, QALY = quality adjusted life year,
ICER = Incremental cost effectiveness ratio. All costs are presented in 2010 Canadian dollars.
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Figure 5.1. Cost-effectiveness plane showing anti-EGFR therapies (panitumumab and
cetuximab) plus best supportive care without KRAS testing.

■

BSC Alone
(No KRAS Test)

A

Panitumumab + BSC
(No KRAS test)

•

Cetuximab + BSC
(No KRAS Test)

■— ■ Not Dominated

5.2 Cost-effectiveness of KRAS testing
I next analyzed the cost-effectiveness of KRAS testing by comparing the
costs and effectiveness of both anti-EGFR therapies (cetuximab and
panitumumab) plus best supportive care with and without KRAS testing (Table
5.2). Compared to panitumumab plus best supportive care with no KRAS testing,
panitumumab plus best supportive care with KRAS testing resulted in a mean
gain of 0.0163 QALYs with an incremental cost of - $6,185 per patient.
Compared to cetuximab plus best supportive care with no KRAS testing,
panitumumab plus best supportive care with KRAS testing resulted in a mean
gain of 0.0281 QALYs with an incremental cost of - $10,037 per patient. My base
case analysis showed that the treatment strategy “panitumumab plus best
supportive care with KRAS testing” dominates all other treatment strategies in
the model (Figure 5.2). Compared to cetuximab plus best supportive care with no
KRAS testing, the cetuximab plus best supportive care with KRAS testing
resulted in a mean gain of 0.01 QALYs with an incremental cost of - $9,394 per
patient.
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Table 5.2. Cost-effectiveness of KRAS gene testing (Markov model 1 and 2)

T r e a tm e n t
stra te g y

Cost p er

In cre m e n ta l

E ffe c tiv e n e s s

In cre m e n ta l

p a tie n t

co st per

p e r p a tie n t

e ffe c tiv e n e s s p e r

p a tie n t

(Q A LY s)

p a tie n t (Q A L Y s)

IC E R

BSC Alone

$1,649

Panitumumab plus BSC
(KRAS test)
Cetuximab plus BSC
(KRAS test)
Panitumumab plus BSC
(No KRAS test)
Cetuximab plus BSC
(No KRAS test)

$25,086

$23,437

0.4886

0.087

$269,703

$25,729

$643

0.4701

-0.0185

Dominated

$31,271

$6,185

0.4723

-0.0163

Dominated

$35,123

$10,037

0.4604

-0.0281

Dominated

0.4017

EGFR = Epidermal growth factor receptor, BSC = best supportive care, QALY = quality adjusted life year, ICER =
Incremental cost effectiveness ratio. All costs are presented in 2010 Canadian dollars.

Figure 5.2. Cost-effectiveness plane of KRAS gene testing.
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0.3
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Effectiveness (QALYs)
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5.3 Cost-effectiveness of anti-EGFR therapies (wild-type KRAS
only)
I also assessed the cost-effectiveness of anti-EGFR therapies (cetuximab
and panitumumab) plus best supportive in subset of patients with wild-type KRAS
(Table 5.3). Compared to best supportive care alone, the incremental cost per
patient for panitumumab plus best supportive (wild-type KRAS) is $37,606. The
panitumumab plus best supportive care (wild-type KRAS) resulted in a mean
gain of 0.16 QALYs, with a mean incremental cost utility ratio of $236,469 per
QALY gained. Compared to cetuximab plus best supportive care in subset of
patients with wild-type KRAS, the panitumumab plus best supportive care
resulted in a mean gain of 0.03 QALYs with an incremental cost of - $1,037 per
patient. My base case cost-effectiveness analysis showed that treatment strategy
“cetuximab plus best supportive care” is dominated by treatment strategy
“panitumumab plus best supportive care” in subset of patients with wild-type
KRAS (Figure 5.3).
Table 5.3. Incremental cost-effectiveness of anti-EGFR therapies (cetuximab and
panitumumab) in subset of patients with wild-type KRAS (Markov model 3)
Treatment
strategy
BSC Alone
Panitumumab
plus BSC
Cetuximab
plus BSC

Cost per
patient

Incremental cost
per patient

Effectiveness
per patient
(QALYs)

Incremental
effectiveness per
patient (QALYs)

ICER

0.4017

$1,649
$39,255

$37,606

0.5607

0.16

$236,469

$40,292

$1,037

0.5309

-0.03

Dominated

EGFR = Epidermal growth factor receptor, BSC = best supportive care, QALY = quality adjusted life year, ICER =
Incremental cost effectiveness ratio. All costs are presented in 2010 Canadian dollars.
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Figure 5.3. Cost-effectiveness plane showing anti-EGFR therapies (panitumumab and
cetuximab) in patients with wild-type KRAS.

■

BSC Alone (No KRAS Test)

a

Panitumumab ♦ BSC (Wild-type KRAS)

•

Cetuximab + BSC (Wild-type KRAS)

Cost-effectiveness Frontier

Effectiveness (QALYs)
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5.4 Deterministic sensitivity analysis
5.4.1 Tornado plot univariate sensitivity analyses for panitumumab
plus best supportive care compared to best supportive care alone
I performed univariate sensitivity analyses to determine which variables
have the greatest influence on cost-utility ratios for panitumumab plus best
supportive care (with KRAS test) compared to best supportive care alone. The
bars in the tornado plot are arranged in descending order based on variation in
incremental cost-utility ratio and each bar corresponds to the model parameter in
front of it. The incremental cost-utility ratios were most sensitive to variation in
utility values and drug cost of panitumumab (Figure 5.4). The dotted line in the
tornado plot represents the mean incremental-cost utility ratio of $269,703 per
QALY gained for panitumumab plus best supportive care compared to best
supportive care alone.
Figure 5.4. Tornado plot univariate analysis for panitumumab plus best supportive care
compared to best supportive care alone.

Utility during progression-free state for panitumumab + BSC
Utility during progression state for BSC Alone
Utility during progression state for panitumumab + BSC
Utility during profression-free state for BSC Alone
Drug cost of panitumumab every 2 weeks
Cost of BSC for panitumumab + BSC every 2 weeks
Specificity of KRAS gene testing
Cost of BSC Alone every 2 weeks
Sensitivity of KRAS gene testing
Cost of KRAS gene testing
Cost of grade 3 or 4 toxicity for panitumumab + BSC
Cost of grade 3 or 4 toxicity for BSC Alone
$180,000

$230,000

$280,000

$330,000

$380,000 $430,000

$480,000

Incremental cost-utility ratio ($ / QALY)

$530,000
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5.4.2 Tornado plot univariate sensitivity analysis for cetuximab plus
best supportive care compared to best supportive care alone
An additional univariate sensitivity analysis was carried out to
determine which variables have greatest influence on cost-utility ratios for
cetuximab plus best supportive care (with KRAS test) compared to best
supportive care alone. The results were quiet similar to my previous sensitivity
analysis for panitumumab plus best supportive care. The incremental cost-utility
ratios were most sensitive to variation in utility values and drug cost of cetuximab
(Figure 5.5). The dotted line in the tornado plot represents the mean incrementalcost utility ratio of $352,046 per QALY gained for cetuximab plus best supportive
care compared to best supportive care alone.
Figure 5.5. Tornado plot univariate analysis for cetuximab plus best supportive care
compared to best supportive care alone.

Utility during progression-free state for cetuximab + BSC
Utility during progression state for BSC Alone
Utility during progression state for cetuximab + BSC
Utility during progression-free state for BSC Alone
Drug cost of cetuximab every 2 weeks
Drug cost of cetuximab for the initial 2 weeks
Cost of BSC for cetuximab + BSC every 2 weeks
Specificity of KRAS gene testing
Sensitivity of KRAS gene testing
Cost of BSC Alone every 2 weeks
Cost of KRAS gene testing
Cost of grade 3 or 4 toxicity for cetuximab
Cost of grade 3 or 4 toxicity for BSC Alone
$230,000

$330,000

$430,000

$530,000

$630,000

Incremental cost-utility ratio ($ / QALY)

$730,000
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5.4.3 Deterministic sensitivity analysis for cetuximab plus best
supportive care compared to panitumumab plus best supportive care
A series of one-way deterministic sensitivity analyses were carried out on
the drug cost of cetuximab. The drug cost of cetuximab was reduced from
original base case value of $3,667 every 2 weeks and the parameter value at
which “cetuximab plus best supportive care” became more cost-effective
treatment strategy than “panitumumab plus best supportive care” was recorded.
At a drug cost of $2,620 every 2 weeks for cetuximab, the treatment strategy
“cetuximab plus best supportive care” became more cost-effective than
“panitumumab plus best supportive care” (Figure 5.6).

Figure 5.6. One-way deterministic sensitivity analysis on drug cost of cetuximab.
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5.4.4 Deterministic sensitivity threshold analysis on the drug cost of
panitumumab
I performed a one-way deterministic sensitivity analysis on the drug cost of
panitumumab (every 2 weeks) until the willingness-to-pay threshold of $50,000
per QALY gained was reached. My analysis showed that by price reduction in
drug cost of panitumumab from $3,359 to $460 every 2 weeks, the treatment
strategy “panitumumab plus best supportive care” resulted in an incremental
cost-utility ratio of $50,000 per QALY gained (Figure 5.7).

Figure 5.7. One-way deterministic threshold sensitivity analysis on drug cost of
panitumumab every 2 weeks.
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5.4.5 Deterministic sensitivity threshold analysis on the cost of KRAS
testing
A series of one-way deterministic sensitivity analyses were performed to
determine the cost value of KRAS testing at which the treatment strategy
“panitumumab plus best supportive care with no KRAS test” becomes a better
strategy than “panitumumab plus best supportive care with KRAS testing” in
terms of cost-effectiveness. My analysis showed that at a KRAS testing cost of
$13,500 per patient, the treatment strategy “panitumumab plus best supportive
care with no KRAS test” becomes a better treatment strategy in terms of costeffectiveness (Figure 5.8).

Figure 5.8. One-way deterministic sensitivity analysis on cost of KRAS gene testing.
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I performed an additional cost-effectiveness analysis by keeping the price
of KRAS testing as $0 to estimate the influence of the cost of KRAS testing in my
economic model (Table 5.4). My analysis showed that the cost of KRAS testing
has a very minimal impact on incremental cost-utility ratios. Compared to best
supportive care alone, the incremental cost per patient for panitumumab plus
best supportive (with KRAS test) is $22,985. The panitumumab plus best
supportive care (with KRAS test) resulted in a mean gain of 0.087 QALYs, with a
mean incremental cost utility ratio of $264,502 per QALY gained.

Table 5.4. Incremental cost-effectiveness of Anti-EGFR therapies (cetuximab and
panitumumab) with KRAS testing cost as zero dollars
Treatment
strategy

Cost per
patient

Incremental
cost per
patient

Effectiveness
per patient
(QALYs)

Incremental
effectiveness per
patient (QALYs)

ICER

0.4017

BSC Alone

$1,649

Panitumumab
plus BSC

$24,634

$22,985

0.4886

0.087

$264,502

Cetuximab
plus BSC

$25,277

$643

0.4701

-0.0185

Dominated

EGFR = Epidermal growth factor receptor, BSC = best supportive care, QALY = quality adjusted life year, ICER =
Incremental cost effectiveness ratio. All costs are presented in 2010 Canadian dollars.

60

5.5 Probabilistic sensitivity analysis
5.5.1 Incremental cost-effectiveness (ICE) scatter plot for
panitumumab plus best supportive care compared to best supportive
care alone
The incremental cost-effectiveness scatter plot comparing panitumumab
plus best supportive care (with KRAS test) to best supportive care alone is
shown in Figure 5.9. The points in the scatter plot represent the comparator’s
(panitumumab plus best supportive care) incremental cost and incremental
effectiveness relative to baseline (best supportive care alone).
The data from probabilistic sensitivity analysis was plotted onto 4
quadrants. The data plotted from probabilistic sensitivity analysis shows that
100% of the samples fell in quadrant I which represents the scenario where
panitumumab plus best supportive care (with KRAS test) is more costly and more
effective than best supportive care alone. The dotted line on horizontal axis
represents the mean incremental effectiveness of 0.087 QALYs gained and the
dotted line on vertical axis represents the mean incremental cost of $23,437 with
a mean incremental cost-utility ratio of $269,703 per QALY gained (95% Cl
based on probabilistic sensitivity analysis = $135,432 to $766,072 per QALY
gained). A 95% confidence ellipse was also drawn in the ICE scatter plot using
TreeAge pro software (TreeAge Software Inc., Williamstown, MA).
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Figure 5.9. Incremental cost-effectiveness scatter plot comparing panitumumab plus best
supportive care (with KRAS test) to best supportive care alone.

5.5.2 Willingness-to-pay threshold analysis for Panitumumab plus
best supportive care compared to best supportive care alone
The cost-effectiveness acceptability threshold analysis for panitumumab
plus best supportive care (with KRAS test) compared to best supportive care
alone is shown in Figure 5.10. The acceptability curve shows the probability of
panitumumab plus best supportive care for being considered cost-effective at
various willingness-to-pay thresholds (ICER values i.e. $ per QALY gained). The
probability of being considered cost-effective is 0% at a threshold of $50,000 per
QALY gained; 0.6% at a threshold of $100,000 per QALY gained; 6.6% at a
threshold of $150,000 per QALY gained; 24.7% at a threshold of $200,000 per
QALY gained and 44.9% at a threshold of $250,000 per QALY gained.
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Figure 5.10. Cost-effectiveness acceptability threshold analysis for panitumumab plus best
supportive care (with KRAS test) compared to best supportive care alone.

5.5.3 Incremental cost-effectiveness (ICE) scatter plot for cetuximab
plus best supportive care compared to best supportive care alone
The incremental cost-effectiveness scatter plot comparing cetuximab plus
best supportive care (with KRAS test) to best supportive care alone is shown in
Figure 5.11. The data plotted from probabilistic sensitivity analysis shows that
98% of the samples fell in quadrant I which represents the scenario where
cetuximab plus best supportive care is more costly and more effective than best
supportive care alone; 2% of the samples fell in quadrant II which represents the
scenario where cetuximab plus best supportive care is more costly but less
effective than best supportive care alone. The dotted line on horizontal axis
represents the mean incremental effectiveness of 0.068 QALYs gained and the
dotted line on vertical axis represents the mean incremental cost of $24,080 with
a mean incremental cost-utility ratio of $352,046 per QALY gained (95% Cl
based on probabilistic sensitivity analysis = $151,916 to $949,342 per QALY
gained). A 95% confidence ellipse was also drawn in the ICE scatter plot using
TreeAge pro software (TreeAge Software Inc., Williamstown, MA).
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Figure 5.11: Incremental cost-effectiveness scatter plot comparing cetuximab plus best
supportive care (with KRAS test) to best supportive care alone.

Incremental Effectiveness (QALYs)

5.5.4 Willingness-to-pay threshold analysis for cetuximab plus best
supportive care compared to best supportive care alone
The cost-effectiveness acceptability threshold analysis for cetuximab plus
best supportive care (with KRAS test) compared to best supportive care alone is
shown in Figure 5.12. The acceptability curve shows the probability of cetuximab
plus best supportive care for being considered cost-effective at various
willingness-to-pay thresholds (ICER values i.e. $ per QALY gained). The
probability of being considered cost-effective is 0% at a threshold of $50,000 per
QALY gained; 0.2% at a threshold of $100,000 per QALY gained; 1.8% at a
threshold of $150,000 per QALY gained; 10.5% at a threshold of $200,000 per
QALY gained and 23.5% at a threshold of $250,000 per QALY gained.
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Figure 5.12. Cost-effectiveness acceptability threshold analysis for cetuximab plus best
supportive care (with KRAS test) compared to best supportive care alone.

5.5.5 Incremental cost-effectiveness (ICE) scatter plot for
panitumumab plus best supportive care compared to cetuximab plus
best supportive care
The incremental cost-effectiveness scatter plot comparing panitumumab
plus best supportive care (with KRAS test) to cetuximab plus best supportive
care (with KRAS test) was produced using TreeAge Pro software (Figure 5.13).
The points in the scatter plot represent the incremental cost and incremental
effectiveness of panitumumab plus best supportive care relative to cetuximab
plus best supportive care. The data from probabilistic sensitivity analysis was
plotted onto 4 quadrants. Quadrant I represent the scenario where panitumumab
plus best supportive care is more costly and more effective than cetuximab plus
best supportive care; 30.9% of the samples fell in this quadrant. Quadrant II
represents the scenario where panitumumab plus best supportive care is more
costly and less effective (i.e. dominated); 13.2% of the samples fell in this
quadrant. Quadrant III represents the scenario where panitumumab plus best
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supportive care is less costly and less effective than cetuximab plus best
supportive care; 19% of the samples fell in this quadrant. Quadrant IV represents
the scenario where panitumumab plus best supportive care is less costly and
more effective (i.e. dominates) than cetuximab plus best supportive care; 36.9%
of the samples fell in this quadrant.
In comparing the effectiveness alone without consideration of costs,
67.8% of the samples (quadrant I & IV) have panitumumab plus best supportive
care more effective than cetuximab plus best supportive care. A 95% confidence
ellipse was also drawn in the ICE scatter plot using TreeAge pro software
(TreeAge Software Inc., Williamstown, MA).

Figure 5.13. Incremental Cost-Effectiveness scatter plot for panitumumab plus best
supportive care compared to cetuximab plus best supportive care.
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5.5.6 Willingness-to-pay threshold analysis for anti-EGFR therapies
I performed a cost-effectiveness acceptability threshold analysis
for anti-EFGR therapies (cetuximab and panitumumab) plus best supportive care
compared to best supportive care alone (Figure 5.14). The acceptability curve
shows the probability of both anti-EGFR therapies (panitumumab and cetuximab)
plus best supportive care for being considered cost-effective at various
willingness-to-pay thresholds (ICER values i.e. $ per QALY gained).

Figure 5.14. Cost-effectiveness acceptability threshold analysis for anti-EGFR therapies.
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5.5.7 Incremental cost-effectiveness scatter plot for panitumumab
plus best supportive care (with KRAS test) compared to
panitumumab plus best supportive care (without KRAS test)
The incremental cost-effectiveness scatter plot comparing panitumumab
plus best supportive care treatment with KRAS testing to panitumumab plus best
supportive care treatment without KRAS testing is shown in Figure 5.15. The
data plotted from probabilistic sensitivity analysis shows that 100% of the
samples fell in quadrant IV which represents the scenario where panitumumab
plus best supportive care with KRAS testing is less costly and more effective (i.e.
dominates) than panitumumab plus best supportive care without KRAS testing.
The dotted line on horizontal axis represents the mean incremental effectiveness
of 0.0163 QALYs gained and the dotted line on vertical axis represents the mean
incremental cost o f-$6,185. A 95% confidence ellipse was also drawn in the ICE
scatter plot using TreeAge pro software (TreeAge Software Inc., Williamstown,
MA).
Figure 5.15. Incremental Cost-effectiveness scatter plot comparing panitumumab plus best
supportive care (with KRAS test) to panitumumab plus best supportive care (without KRAS
test).
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5.5.8 Incremental cost-effectiveness scatter plot for panitumumab
plus best supportive care (wild-type KRAS) compared to best
supportive care alone
The incremental cost-effectiveness scatter plot comparing panitumumab
plus best supportive care (in subset of patients with wild-type KRAS) to best
supportive care alone is shown in Figure 5.16. The data plotted from probabilistic
sensitivity analysis shows that 100% of the samples fell in quadrant I which
represents the scenario where panitumumab plus best supportive care (wild-type
KRAS) is more costly and more effective than best supportive care alone. The
dotted line on horizontal axis represents the mean incremental effectiveness of
0.16 QALYs gained and the dotted line on vertical axis represents the mean
incremental cost of $37,606 with a mean incremental cost-utility ratio of $236,469
per QALY gained (95% Cl based on probabilistic sensitivity analysis = $125,259
to $557,750 per QALY gained). A 95% confidence ellipse was also drawn in the
ICE scatter plot using TreeAge pro software (TreeAge Software Inc.,
Williamstown, MA).
Figure 5.16. Incremental cost-effectiveness scatter plot for panitumumab plus best
supportive care (Wild-type KRAS) compared to best supportive care alone.
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5.5.9 Willingness-to-pay threshold analysis for panitumumab plus
best supportive care (wild-type KRAS) compared to best supportive
care alone
I constructed a cost-effectiveness acceptability threshold analysis
for panitumumab plus best supportive care (wild-type KRAS only) compared to
best supportive care alone is shown in Figure 5.17. The acceptability curve
shows the probability of panitumumab plus best supportive care (in subset of
patients with wild-type KRAS) for being considered cost-effective at various
willingness-to-pay thresholds (ICER values i.e. $ per QALY gained). The
probability of being considered cost-effective is 0% at a threshold of $50,000 per
QALY gained; 0.9% at a threshold of $100,000 per QALY gained; 11.1% at a
threshold of $150,000 per QALY gained; 33.5% at a threshold of $200,000 per
QALY gained and 56.5% at a threshold of $250,000 per QALY gained.

Figure 5.17. Cost-effectiveness acceptability threshold analysis for panitumumab plus best
supportive care (wild-type KRAS) compared to best supportive care alone.
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Chapter 6: Discussion & Conclusions
6.1 Discussion
My economic analysis is the first to examine the cost-effectiveness of two
anti-EGFR monoclonal antibodies (panitumumab and cetuximab) versus best
supportive care alone in a single economic model. To my knowledge it is also the
first economic analysis to analyze the cost-effectiveness of KRAS testing using
the survival data from two phase III clinical trials.
In this economic analysis, panitumumab plus best supportive care and
cetuximab plus best supportive care showed high incremental cost-utility ratios
(ICER = $269,703 for panitumumab and $352,040 for cetuximab with KRAS
testing) when compared with best supportive care alone. The base case and
sensitivity analysis showed that among anti-EGFR therapies, panitumumab
based therapy was much more cost effective than cetuximab based therapy for
treatment of advanced metastatic colorectal cancer. The probabilistic analysis
showed that, in comparing the effectiveness alone without consideration of costs,
67.8% of the time panitumumab plus best supportive care was more effective
than cetuximab plus best supportive care.
This economic evaluation clearly showed the importance and advantage
of KRAS testing in terms of both reduced costs and higher effectiveness in
treatment of advanced metastatic colorectal cancer with anti-EGFR therapies
(panitumumab and cetuximab). The incremental cost-utility ratios were
significantly lower and had narrower 95% confidence intervals for the subset of
patients with wild-type KRAS, indicating the potential benefit of treatment with
anti-EGFR therapies limited to patients with wild-type KRAS only. However, the
cost-effectiveness acceptability curves showed that the probability of
panitumumab plus best supportive care (in subset of patients with wild-type
KRAS) being considered cost-effective was 0% at a willingness-to-pay threshold
value of $50,000 per QALY gained, 0.9% at a threshold value of $100,000 per
QALY gained, and 56.5% at a threshold value of $250,000 per QALY gained.
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The drug costs of both panitumumab and cetuximab were a major cost
driver in my economic analysis. My sensitivity analysis showed that incremental
cost-utility ratios were most sensitive to drug costs amongst all cost parameters
in the analysis. The incremental cost-utility ratio for panitumumab plus best
supportive care (with KRAS test) reached the willingness-to-pay threshold of
$50,000 per QALY gained at a drug cost of $460 bi-weekly.
Economic evaluations are conducted to help provide the “value for money”
information to decision and policy makers about resource allocation in a resource
constrained environment [52]. Most countries such as Canada, the United
Kingdom and Australia require a formal structured economic evidence for drug
reimbursement [60, 68], Cost-effectiveness analysis has been increasingly
becoming the analytic method choice to help inform the reimbursement decisions
for oncology medications by weighing the incremental costs and consequences
of alternative treatment strategies being compared [60, 68]. Implicit incremental
cost-effectiveness ratio (ICER) thresholds for drug reimbursement
recommendations have been published in Australia and the United Kingdom [68],
In Canada, no such implicit economic thresholds have been published [68]
but the evidence from existing literature suggests that the treatment strategies
with “attractive” ICER are more likely to be positively recommended for drug
reimbursement than treatment strategies with less attractive ICER [68]. An ICER
range of $20,000 to $100,000 per QALY is considered as a reasonable boundary
for determining whether a new medical intervention is cost-effective [68, 69]. In
most Canadian territories (except Quebec), the drug reimbursement
recommendations to Canadian publicly funded drug plans are made by the
Canadian Common Drug Review (CDR) [70], The CDR considers various factors
such as drug effectiveness, drug costs, drug toxicity, ethical and societal issues,
and existing pharmaco-economic evaluations for making drug reimbursement
recommendations [70]. These recommendations are further reviewed by the
Canadian Expert Drug Advisory Committee (CEDAC - a committee of 11
physicians, pharmacists and nurses) [70]. The CEDAC recommends one of three
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possible options for drug reimbursement: fund the drug without restrictions; fund
the drug with restrictions; and do not fund the drug [70],
The clinical evidence to support the benefit is stronger for oncology
medications [68, 71] and they are usually adopted at the highest threshold of
acceptability than non-oncology medications [68, 71]. Recent recommendations
from Canadian Expert Drug Advisory committee (CEDAC) suggest that an ICER
threshold of $75,000 per QALY may be considered acceptable for oncology
medications [68], A 2006 survey of medical oncologists inferred a willingness-topay threshold of up to $300,000 per QALY gained acceptable for oncology
medications [72] but it is important to note that there is no empirical evidence to
support such a threshold.
Table 6.1. Summary table
Model*

Treatment strategy

ICER

Panitumumab plus BSC
$419,528
(No KRAS test)

Markov model 1
Cetuximab plus BSC
dominated
(No KRAS test)
Panitumumab plus BSC

$269,703

(with KRAS test)
M a rk o v m odel 2
Cetuximab plus BSC
dominated
(with KRAS test)
Panitumumab plus BSC

$236,469

(wild-type KRAS only)
M a rk o v m odel 3
Cetuximab plus BSC
dominated
(wild-type KRAS only)

In the Markov model 1, 2 and 3, the baseline treatment strategy is best supportive care alone (No KRAS test).
ICER= Incremental cost-effectiveness ratio, BSC = best supportive care, All costs are presented in 2010 Canadian
dollars.
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6.2 Limitations
This economic analysis has several possible limitations. First, the utility
weights used in the economic analysis were obtained from two different studies
which used different health-related quality of life (HRQoL) instruments to
measure utility values. The utility weights for cetuximab plus best supportive care
were calculated using Health Utilities Index Mark 3 (HUI3) [60, 62] and utility
weights for panitumumab plus best supportive care were calculated using
Euroqol-5D (EQ-5D) [61, 63]. The use of different HRQoL instruments to assign
quality of life scores (utilities) to health states may have some impact on overall
effectiveness calculated in my model but I performed a series of deterministic
and probabilistic sensitivity analyses to assess the robustness of the results.
Second, the economic analysis is based on survival and drug toxicity data
obtained from clinical trials [8, 9], Thus, results may not be generalizable to
routine care of advanced metastatic colorectal cancer patients.
Third, the best supportive care costs were assumed to be the same for
both panitumumab and cetuximab. However these costs may be different in
routine care of advanced metastatic colorectal cancer patients with these drugs.
My sensitivity analysis showed that best supportive care costs did not have a
significant influence on the model outcome (incremental cost-utility ratios).
Fourth, the time horizon of 2 years for my economic analysis was based
on maximum time of follow-up in both trial studies (1.58 years for NCIC CTG
CO. 17 trial and 2 years for Open-Label Phase III trial) [8, 9]. However, it is
unlikely that there would be any statistically significant survival gain beyond time
horizon of my economic model that could impact model outcome, as fewer than
10% of the patients were alive at the end of 2 years in both trials [8-9, 15-16].
Fifth, my economic analysis was based on multinational clinical trials
which may be subject to geographical and jurisdictional differences in the patient
population, health care costs, health care resources allocation and utilization [73,
74].
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Sixth, In the open-label phase III trial, the treatment arm (panitumumab
plus best supportive care) had 54% of the patients with ECOG performance
status of 1 and 2 as compared to 66% in control arm (best supportive care alone)
[8], This difference is a potential limitation of the clinical trial as it could have
impacted the overall survival and progression free survival among the treatment
groups.

6.3 Conclusion
From a cost-effectiveness perspective, both anti-EFGR therapies
(panitumumab and cetuximab) showed very high Incremental cost-utility ratios
and were not cost-effective at a willingness-to-pay threshold of $100,000 per
QALY. The cost-effectiveness of both anti-EGFR therapies (panitumumab and
cetuximab) as compared to best supportive care alone with KRAS testing
dominates the cost-effectiveness without KRAS testing and the incremental costutility ratios became more favourable. However, even with KRAS testing, both
anti-EGFR therapies were not cost-effective at a willingness to pay threshold of
$100,000 per QALY.
In most cases, among anti-EGFR therapies, the treatment option with
panitumumab plus best supportive care dominates the treatment option with
cetuximab plus best supportive care as third-line therapy for treatment of
advanced metastatic colorectal cancer.
The cost-utility ratios for both anti-EGFR therapies (panitumumab and
cetuximab) as compared to best supportive care alone were significantly lower
and had narrower 95% confidence intervals in subset of patients with wild-type
KRAS. This suggests that personalizing advanced metastatic colorectal cancer
treatment based on KRAS mutation status could not only save health care
system substantial sums but also spare thousands of patients with colorectal
cancer from side effects of the anti-EGFR therapy that are unlikely to benefit from
the treatment.

Appendix I (Release of information letter from AMGEN)

76

/«VIGEN’
Medical Information

August 25, 2010
Dr. Muhammad Ali
157-1560 Adelaide St. North
London, ON N5X 2C1
Dear Dr. Ali:
Thank you for your request to Amgen Canada Inc. for information regarding the following topic(s),
which was forwarded to our department on your behalf by Ben Ofori.
•

Vectibix™ (panitumumab) - quality of life and cost

Please find enclosed the following references in response to your request.
•Siena S, Peeters M, VanCutsem E, et al. Association of progression-free survival with
patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab.
Britis Journal of Cancer 2007;97:1469-1474.
•Peetrs M, PRice T, Hotko Y, et al. Randomized Phase 3 Study of Panitumumab with FO LFIRI
vs FO LFIR I alone as 2nd-Line Treatment in Patients with Metastatic Colorectal Cancer (mCRC):
Patient Reported Outcomes (PRO). Poster presented at
•Mancl E, Kolesar J, Vermeulen L. Clinical and economic value of screening for Kras mutations
as predictors of response to epidermal growth factor receptor inhibitors. Am J Health-Syst Pharm
2009;66:e17-24.
•Bracco A, Farrimond B J, Fitzgibbon JW, et al. A Model to Demonstrate the Comparative Costs
Between Panitumumab and Cetuximab for Third-line Metastatic Colorectal Cancer Patients in Italy.
Poster presented at IS P O R Annual European Congress Athens, Greece; November 8-11, 2008.
•Graham C, Borker R, Oppe M, et al Cost-effectiveness of Panitumumab Plus Best Supportive
Care Compared With Best Supportive Care Alone in Chemorefractory Metastatic Colorectal
Cancer Patients With Wild-Type K R A S Tumor Status in the Netherlands. ESMO, Stockholm,
Sweden; September 12-16, 2008
We are providing you with this material as an information service and professional courtesy. It is
intended to provide pertinent data that will assist you in forming your own conclusions and making
your own decisions. It is not intended to recommend new uses for our products. Amgen Canada
Inc. recommends the use of its products only in accordance with the Health Canada Approved
Product Monograph.

AMGEN Canada Inc., 6775 Financial Drive, Ste. 100, Mississauga, Ont. L5N 0A4
Tel: 1-866-502-6436 Fax: 1 866-472-6436 Email: metlinfocanacla@amgen.com
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Please note that your contact information and request for information will be retained in our
electronic database to facilitate delivery of the requested information and to comply with applicable
laws. Please contact us should you have any questions or concerns about the retention of this
information.
Should you have any additional questions, please contact our Medical Information Department at
1-866-502-6436 or via e-mail at medinfocanada@amgen.com.
Sincerely,

Diane Lord, B.Pharm.
Medical Information Manager

1-793779111
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